Articles
23 June 2009
Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
https://doi.org/10.4081/hmr.v2i5.743

Pha-739358: a pan-aurora kinase inhibitor

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
257
Views
442
Downloads

Authors

R Paquette
support@pagepress.org
N Shah
C Sawyers
G Martinelli
J Nicoll
M Chalukya
PHA-739358 is a small molecule 3-aminopyrazole derivative with low nanomolar activity against all aurora kinases (AKs). It also inhibits other cancer relevant tyrosine kinases such as wild type and mutated ABL, RET, TRK-A and FGFRs.1,2 PHA-739358 shows a dominant aurora kinase B inhibition-related cellular phenotype and induces a p53 status dependent endoreduplication. The compound has antitumor activity in spontaneous, transgenic and xenograft models of solid and hematologic tumors with occasional cures. It is active in a broad range of BCR-ABL positive and negative cell lines, including T315I BCR-ABL mutants. A decreased phosphorylation of histone H3 under PHA- 739358 treatment has been described as a pharmacodynamic biomarker of aurora kinase B inhibition in human skin at safe doses. Similarly the reduced CRKL phosphorylation documents the activity via BCR-ABL inhibition.1,3

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Pha-739358: a pan-aurora kinase inhibitor. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.743